ArticleAdvances in therapy2026
Return of Mailed Multitarget Stool DNA Test Kits and Subsequent Colorectal Cancer Incidence in the United States: A Retrospective Cohort Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCompletion of colorectal cancer (CRC) screening is essential to realizing the benefits of early detection and prevention; however, many individuals do not complete screening after a test is provided. The association between screening completion and subsequent CRC incidence remains poorly understood. We evaluated the association between multitarget stool DNA (mt-sDNA) test kit return and CRC incidence among average-risk adults.
methodsThis retrospective cohort study, linking claims data from Komodo Health with Abbott laboratory data, included adults aged 45-85 years who received an mt-sDNA kit between January 1, 2017, and December 31, 2019 (based on linked laboratory and claims data). The primary outcome was incident CRC identified using claims-based diagnosis codes. Propensity score-matched (PSM) and inverse probability treatment-weighted (IPTW) analyses assessed robustness to confounding. Adjusted incidence rate ratios (IRRs) were estimated using Poisson regression and hazard ratios (HRs) using Cox proportional hazards models.
resultsThe cohort included 2,574,759 adults (60.5% female, 38.5% male; 68.2% White, 8.2% Black/African American, 6.5% Hispanic, 2.6% Asian/Pacific Islander, 14.4% other/unknown race), who contributed over 14 million person-years of follow-up. CRC incidence was lower among kit returners than non-returners (248.95 vs 301.89 per 100,000 person-years). In adjusted analyses, mt-sDNA kit return was associated with 55% lower CRC incidence versus non-return [IRR 0.45; 95% confidence interval (CI) 0.45-0.46; p < 0.0001], with similar findings in PSM (IRR 0.58; 95% CI 0.57-0.59) and IPTW analyses (IRR 0.28; 95% CI 0.28-0.28). Supportive time-to-event analyses demonstrated directionally consistent associations, with mt-sDNA kit return associated with improved CRC-free survival (HR 0.76; 95% CI 0.74-0.78; p < 0.0001).
conclusionsIn this large retrospective cohort study, mt-sDNA screening completion was consistently associated with lower CRC incidence across unmatched, PSM, and IPTW analyses. These findings support strategies to improve stool-based CRC screening completion to maximize the population-level benefits of CRC screening programs.
Indexed as
Identifiers
42859933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.